Peter Berglund
Overview
Explore the profile of Peter Berglund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Warner N, Archer J, Park S, Singh G, McFadden K, Kimura T, et al.
Sci Transl Med
. 2024 Aug;
16(759):eadi1625.
PMID: 39110777
The recent emergence and rapid response to severe acute respiratory syndrome coronavirus 2 was enabled by prototype pathogen and vaccine platform approaches, driven by the preemptive application of RNA vaccine...
2.
Rocha V, Machado B, Barreto B, Quadros H, Fernandes A, Lima E, et al.
Heliyon
. 2024 Feb;
10(4):e25539.
PMID: 38370238
Immune imprinting is now evident in COVID-19 vaccinated people. This phenomenon may impair the development of effective neutralizing antibodies against variants of concern (VoCs), mainly Omicron and its subvariants. Consequently,...
3.
Seo Y, Lu H, Black G, Smythe K, Yu Y, Hsu C, et al.
JAMA Oncol
. 2023 Oct;
9(12):1660-1668.
PMID: 37824131
Importance: Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist glycopyranosyl...
4.
Kimura T, Leal J, Simpson A, Warner N, Berube B, Archer J, et al.
Mol Ther
. 2023 Jul;
31(8):2360-2375.
PMID: 37403357
RNA vaccines possess significant clinical promise in counteracting human diseases caused by infectious or cancerous threats. Self-amplifying replicon RNA (repRNA) has been thought to offer the potential for enhanced potency...
5.
Morse M, Crosby E, Force J, Osada T, Hobeika A, Hartman Z, et al.
Cancer Gene Ther
. 2023 Feb;
30(6):803-811.
PMID: 36765179
Therapeutic cancer vaccines, designed to activate immune effectors against tumor antigens, utilize a number of different platforms for antigen delivery. Among these are messenger RNAs (mRNA), successfully deployed in some...
6.
Piras F, Plitnick L, Berglund P, Bernard M, Desert P
J Appl Toxicol
. 2022 Oct;
43(4):534-556.
PMID: 36227735
Herpes simplex virus type 2 (HSV-2) is the most common cause of genital disease worldwide. The development of an effective HSV-2 vaccine would significantly impact global health based on the...
7.
Hawman D, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal S, et al.
EBioMedicine
. 2022 Aug;
83:104196.
PMID: 35932641
Background: In late 2021, the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC) was reported with many mutations in the viral spike protein that were predicted to enhance transmissibility and allow...
8.
Hawman D, Meade-White K, Archer J, Leventhal S, Wilson D, Shaia C, et al.
Elife
. 2022 Feb;
11.
PMID: 35191378
Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late 2021 with resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants of concern...
9.
Hawman D, Meade-White K, Archer J, Leventhal S, Wilson D, Shaia C, et al.
bioRxiv
. 2021 Dec;
PMID: 34931189
Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late-2021 with resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants of concern (VoC)...
10.
Leleux J, Albershardt T, Reeves R, James R, Krull J, Parsons A, et al.
PLoS One
. 2021 Dec;
16(12):e0259301.
PMID: 34855754
Systemic interleukin-12 (IL12) anti-tumor therapy is highly potent but has had limited utility in the clinic due to severe toxicity. Here, we present two IL12-expressing vector platforms, both of which...